Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter retrospective study from a cohort of eight US academic centers (LEO CReWE), we evaluated 183 patients with R/R DLBCL and high-grade B cell lymphoma treated with R-GemOx, including subgroups treated without intent for consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T cell therapy (n = 100), those utilizing R-GemOx as a bridge to ASCT or CAR T (n = 83), and those aged 70 and older (n = 71). Overall response rates (ORRs) for all patients treated with R-GemOx were 45% with a complete response (CR) rate of 29%. The median event-free survival (EFS) was 2.3 months, and the median overall survival (OS) was 13.5 months. Patients receiving R-GemOx without intent for ASCT or CAR T had ORR and CR rates of 33% and 18%, respectively, with median EFS and OS of 2.0 and 9.5 months, respectively. Patients receiving R-GemOx as a bridge to ASCT or CAR T had ORR and CR rates of 57% and 36%, respectively, with median EFS and OS of 3.5 and 17.4 months, respectively. Patients receiving R-GemOx aged 70 and older had ORR and CR rates of 53% and 33%, respectively, with median EFS and OS of 2.2 and 13.9 months, respectively. These data provide a benchmark for R-GemOx in the rapidly evolving landscape of R/R DLBCL therapies.
Authors
- Jonathon Brett Cohen (ORCID: https://orcid.org/0000-0002-2723-6481)
- Sara Haddadi (ORCID: https://orcid.org/0009-0000-4909-3541)
- Thomas Matthew Habermann (ORCID: https://orcid.org/0000-0003-3532-9132)
- Loretta J. Nastoupil (ORCID: https://orcid.org/0000-0001-6071-8610)
- Peter Martin (ORCID: https://orcid.org/0000-0001-7813-1551)
- Connie Lee Batlevi (ORCID: https://orcid.org/0000-0002-9036-9463)
- Anthony Masaquel
- Izidore S. Lossos (ORCID: https://orcid.org/0000-0002-9346-9013)
- Dai Chihara (ORCID: https://orcid.org/0000-0002-1153-2294)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Grzegorz S. Nowakowski (ORCID: https://orcid.org/0000-0002-6955-9393)
- Ashwini Shewade
- Amy A. Ayers (ORCID: https://orcid.org/0000-0003-4807-2356)
- Carla Casulo (ORCID: https://orcid.org/0000-0003-4998-9932)
- Michele Stanchina (ORCID: https://orcid.org/0000-0002-4691-7645)
- Brad S. Kahl (ORCID: https://orcid.org/0000-0003-0459-6609)
- Arushi Khurana (ORCID: https://orcid.org/0000-0001-5645-0949)
- James R. Cerhan (ORCID: https://orcid.org/0000-0002-7482-178X)
- David Fox (ORCID: https://orcid.org/0000-0002-5465-1648)
- Christopher R. Flowers (ORCID: https://orcid.org/0000-0002-9524-3990)
- Brian K. Link (ORCID: https://orcid.org/0000-0001-5084-0698)
- Jean Louise Koff (ORCID: https://orcid.org/0000-0003-4414-0489)
- Samuel Yamshon (ORCID: https://orcid.org/0000-0002-4616-8568)
- Tanner W. Reicks
- Umar Farooq (ORCID: https://orcid.org/0000-0001-7891-9891)
- Yucai Wang (ORCID: https://orcid.org/0000-0002-1576-8341)
- Melissa C. Larson (ORCID: https://orcid.org/0000-0002-5430-8161)
- Yong Mun
- Jia Li (ORCID: https://orcid.org/0009-0000-6922-3163)
- Andrea Lo‐Rossi
Institutions
- University of Iowa (US)
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Mayo Clinic in Florida (US)
- Sylvester Comprehensive Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Rochester (US)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1002/ajh.27630
- Citations
- 9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- National Institutes of Health
- Genentech